✦ LIBER ✦

Cardiovascular Events with De Novo Use of Everolimus in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study

✍ Scribed by Potena, L.; Schultz, U.; Bara, C.; Arizon, J.M.; Dong, G.; Lopez, P.; Epailly, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

24-month safety results of a randomized,

✍ H Eisen; J Kobashigawa; R.C Starling; N Cretin; J.S Jaffe; J Murphy 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Adverse Events (AEs) Associated with Eve

✍ Eisen, H.; Ross, H.; Pauly, D.; Kfoury, A.; Van Bakel, A.; Starling, R.; Patel, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Safety of Early Everolimus in De Novo He

✍ Potena, L.; Barberini, F.; Boffini, M.; Amarelli, C.; Pellegrini, C.; Livi, U.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 240 KB

171 Lower Incidence of Viral Infections

✍ H. Ross; A.G. Kfoury; A. Van Bakel; G. Ewald; J. Burton; A. Andreassen; J. Segov 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 75 KB

12-month safety and efficacy of everolim

✍ Helio Tedesco-Silva Jr; Stefan Vitko; Julio Pascual; Josette Eris; John C. Magee 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 504 KB

466: Hospitalization Days Due to Major C

✍ H. Lehmkuhl; J. Arizon; L. Almenar; C. Magelli; G. Gerosa; S. Varnous; F. Musume 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB